Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is a promising biopharmaceutical company with a strong commercial presence and a promising drug candidate, VTAMA, in the plaque psoriasis market. Despite a decline in 4Q26 revenue and an increase in non-GAAP expenses, the company has a solid financial position with a cash runway into profitability. The company's diversified pipeline, particularly with its anti-FcRn franchise, provides multiple potential growth opportunities and mitigates potential risks.

Bears say

Roivant Sciences is facing strong competition in the biopharmaceutical industry and their current drug candidate, VTAMA, has limited potential with only one indication for treatment. Furthermore, the company's strategy of incubating discovery-stage companies and health technology startups may not be sustainable in the long term. With a lack of diversity in their drug pipeline and the potential for increased regulation risks, Roivant Sciences has a high-risk profile and is not a strong investment opportunity.

ROIV has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 10 analysts, ROIV has a Buy consensus rating as of Jun 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.